CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine

Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.

Frontiers CD38 Predicts Favorable Prognosis by Enhancing Immune Infiltration and Antitumor Immunity in the Epithelial Ovarian Cancer Microenvironment

CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

Toward personalized treatment approaches for non-small-cell lung cancer

Frontiers Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity

2023 ASPHO Conference Paper and Poster Index - 2023 - Pediatric Blood & Cancer - Wiley Online Library

Volume 8, issue 1 Multidisciplinary Respiratory Medicine

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

PDF) Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy

Frontiers Role of CD38 in anti-tumor immunity of small cell lung cancer

Cancers, Free Full-Text

Frontiers The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies

Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance - ScienceDirect

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Cancers, Free Full-Text

Non-Small Cell Lung Cancer Market report 2023-2033 - Wissen Research